Safety and clinical efficacy evaluations
nausea, leukopenia, Treatment-related adverse events, bone marrow suppression, anorexia, rashes
ADVERSE REACTIONS, LEUKOPENIA, BONE MARROW SUPPRESSION, ADVERSE DRUG REACTIONS, ANOREXIA
Among the enrolled patients, 17 underwent two cycles of pembrolizumab combined with chemotherapy, and 5 underwent three cycles. These 5 patients received an additional cycle because their surgery was delayed by the COVID-19 epidemic. None of the patients had delayed surgery due to adverse drug reactions. The safety evaluation of pembrolizumab combined with preoperative neoadjuvant chemotherapy recorded 2 patients with grade 3 adverse reactions, both of which were leukopenia caused by bone marrow suppression and no grade 4 adverse reactions. The most common grade 1 or 2 adverse reactions were nausea and anorexia (n = 6), followed by rashes (n = 3) and weakness (n = 3) (Treatment-related adverse events (TRAEs).